Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. - Wikidata - wikimedia - TriplyDB

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

http://www.wikidata.org/entity/Q36431654

about

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Diabetes, bone and glucose-lowering agents: clinical outcomes.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Ketoacidosis and SGLT2 inhibitor treatment: Analysis of FAERS data.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.Diabetes Drug Effects on the Skeleton.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Canagliflozin: A Review in Type 2 Diabetes.Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.SGLT2 inhibitors: are they safe?Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.Weak bones in diabetes mellitus - an update on pharmaceutical treatment options.Initiation of dapagliflozin and treatment-emergent fractures.Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.Adverse bone effects of medications used to treat non-skeletal disorders.The Impact of Type 2 Diabetes on Bone Fracture Healing.Efficacy and safety of sotagliflozin in treating diabetes type 1.The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.

P2860

Q26777529-56665EA9-D44E-422E-A153-F47022860F13 Q30234622-AC72718B-0341-4D4D-B7B3-872DD67DBDBD Q30249371-0B5EB637-0CB8-49B5-ACCA-7B22AC1F78D1 Q33625568-5964E0AB-B479-48B6-AC4A-557CC79FF23D Q33691585-F46E5793-54FB-4DD8-B44C-ED84D4F62E88 Q36431670-32ABC8F0-8B9F-4AB1-B0DC-8E13FE9B2188 Q37511845-72A2A37D-F5D0-4863-94A0-EA200A60A3AF Q37661798-F9E5F8A7-F7C3-4362-99A1-BD65AE659AD3 Q37737458-1B101F12-54BF-4635-A42F-BEF8053E532D Q37741752-720A062E-AEFF-472D-B1C8-118C752701C7 Q38371417-C43F5C20-FCCF-45CE-A255-FED055A586D9 Q38658251-376B021C-EA3C-4DCC-B5B5-10128D4CFA36 Q38665387-3D7757CC-DFB0-462C-8313-30CE22C5315A Q38798654-F4F24DFB-152F-41C9-BBF0-B06223088680 Q38821464-B2BBE946-89B4-4C3E-9230-CFD603A2C3E0 Q38842559-0BEA7B41-586A-453D-8D88-C7877CACB170 Q38863649-CECF852A-C274-49CE-A27A-183863CB81E0 Q38906041-A9C097DB-37C3-4E2B-A914-7CFFDF9D2076 Q38908779-8CED3F56-76D8-4C26-875C-52C678AC382F Q38931842-EDC26F41-96E9-4C50-A8BC-ABC4E690AA50 Q38973384-14232A8D-0958-4B64-AF60-6F3254DDD3D4 Q38999214-83ED28B9-0D27-4BA4-9077-D01559150C30 Q39000587-BAF183D1-B885-47D7-AE91-E2A73F7EF37F Q39003573-E8ACE5BB-F99C-4461-96AF-B1EB98871282 Q39022309-ADB5B3CE-65FF-476C-A0B2-92F4E85A3E05 Q39023661-85A5BCCB-8686-4463-A12E-B0295ECE69FB Q40081685-CFF65637-3967-4737-B764-009CA3BC3E81 Q40581771-9670E209-6216-48B3-B7EB-C837FDBB8814 Q45718716-FB3C6D9F-6DEE-448B-B284-7A99BD79F151 Q47316565-732F8898-0138-4563-9912-13C034ED6B1D Q47642298-98F8CFB2-4167-49FC-9E6E-1C1D0ECA97FB Q47652080-28BCFD14-B72A-41B5-AE1B-57F4E7B65A71 Q47700645-02C40817-25CF-4BE9-A14E-9541A4AD3907 Q47855337-604B7FA8-0DFE-402E-9F6F-A02F33E4A2D4 Q48200971-DB946531-4517-4FBD-8131-7062A759460F Q48235609-CE2CF9BB-67E6-450A-8AF9-DB825CFA64CF Q48332195-49E12E48-1C50-4A29-99D8-DB428223484E Q49294423-2A2DE0D7-9AED-4439-8A26-3011ACAEF15D Q50047534-D7597DD2-B586-4D28-BD7F-6C96E591140D Q51746289-BD6B5119-A309-4F01-A9C0-DCCD203373EB

P2860

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

http://www.wikidata.org/entity/Q36431654

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@ast

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@en

type

label

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@ast

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@en

prefLabel

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@ast

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@en

P1433

Q36431654-F4C47A0C-83ED-43E5-9DC1-2B3091948BE7

P1476

Q36431654-8CB7B451-F30B-4B69-A58A-18EC51D00FAB

P2093

Q36431654-1B5BDA83-F4AB-45B9-AF1F-90AA443B3CD2

Q36431654-21827958-4885-4FCB-9FAF-541D94C781D0

Q36431654-2701C06F-E29D-40C8-B6DF-6031970CCBEB

Q36431654-61711E8E-DAFA-4661-A19C-C873428E8879

Q36431654-BA7C6B0A-0422-4BD4-B202-C20D50A20FD8

Q36431654-F2899C5E-4E61-4616-A039-4960CF8027A5

P2860

Q36431654-03151255-9A5A-4D72-8DFE-D9A2F0AE143F

Q36431654-068E82A9-4C2E-4A99-A510-355108522468

Q36431654-0CCDC37E-3996-4A73-897F-F7786E317DCF

Q36431654-183FD5DB-CA1D-4A88-B5F8-166D065AB802

Q36431654-18DE11CF-64A8-4F5B-AB9A-57239F022012

Q36431654-1BA73B9E-6E89-4CE3-9689-7E5132037531

Q36431654-35895DCD-EA9A-4681-B953-7C99970CE861

Q36431654-4BB8D4E9-2DF2-4083-A29F-1982ADDD63C4

Q36431654-4C0E804B-32BF-4FD8-AA20-53E4B83C58E0

Q36431654-5BDECC4F-1A14-4816-AB09-0EED99D0B8E4

P304

Q36431654-6C074C9C-3185-4A85-B539-0B4FB10FFD07

P31

Q36431654-EF541244-3DAC-4E5B-8084-198C123D81F2

P356

Q36431654-0F6BDC06-A175-4B14-8D1E-B813CC145F7D

P407

Q36431654-A1D07BCE-B2C6-4390-8142-84467628807E

P433

Q36431654-8A0A4546-FEDB-45C8-8973-D0BACA4B16A3

P478

Q36431654-EE8AD11D-BD84-43F3-B9C3-41FBB7CF8423

P50

Q36431654-05309BA7-7060-4301-8CE5-78A83EA583D1

P577

Q36431654-27421D94-194E-4A85-A3AB-D6A1C9AA1EC3

P698

Q36431654-2C355B22-02ED-45FA-9BFF-C6253E97D324

P921

Q36431654-E2B9F4BA-0B38-4E00-885E-D8BA68FC395A

Q36431654-F9DD961A-0EB9-4BBE-BFEB-0F2FB071B7BC

P932

Q36431654-B7ED1B4A-29A2-45B5-901F-9920AD982C0A

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Evaluation of Bone Mineral Den ...... es Treated With Canagliflozin.

@en

P2093

Albert Fung

http://www.w3.org/2001/XMLSchema#string

Daniel Sullivan

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Keith Usiskin

http://www.w3.org/2001/XMLSchema#string

Nelson B Watts

http://www.w3.org/2001/XMLSchema#string

Norm Rosenthal

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Effect of Roux-en Y gastric bypass on bone metabolism in patients with morbid obesity: Mansoura experiences.

The role of fat and lean mass in bone loss in older men: findings from the CHAMP study.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

P304

44-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2015-1860

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

John P. Bilezikian

P577

2015-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26580234

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4701848

http://www.w3.org/2001/XMLSchema#string